FOR LABORATORY RESEARCH USE ONLY — not for human or veterinary use, diagnosis, treatment, or cosmetic application. Buyers must be 21+ and legally permitted to purchase research chemicals in their jurisdiction.Intended-use statement →
Tirzepatide Wholesale
39-amino acid dual GIP/GLP-1 receptor agonist — the differentiation leader in metabolic peptide portfolios
Product Identity
| CAS Number | 2023788-19-2 |
| Sequence | 39-amino acid with Aib²+Aib¹³ + C20 fatty diacid linker + C-terminal amidation |
| Molecular Weight | ~4,813.5 Da |
| Appearance | White to off-white lyophilized powder |
| Purity | ≥99% by HPLC |
| Solubility | Phosphate buffer (pH 7.4) or dilute acetic acid |
| Storage | 2–8°C, desiccated, protect from light |
Factory-directShenzhen, China
Available Configurations
| Configuration | Content | Best For |
|---|---|---|
| Standard Kit | 5 mg × 10 vials | Most protocols; evaluation |
| Bulk Kit | 10 mg × 10 vials | High-throughput; OEM |
| Custom | Custom mg × custom vials | Private-label; protocol-specific |
Research Background
Tirzepatide is an imbalanced dual agonist — it activates both GIP and GLP-1 receptors but with ~5× greater GIPR potency. This dual mechanism is the basis for its enhanced metabolic efficacy over selective GLP-1 agonists.
Proposed Mechanisms
Research Focus Areas
~22.5% mean reduction (SURMOUNT-1); >GLP-1 alone
HbA1c reduction up to 2.4%; superior to Semaglutide 1mg
Improved lipid profiles; reduced triglycerides
Improved beyond weight loss alone (GIP-mediated)
Reduced liver fat content; under investigation for NASH
Quality Specifications
| Parameter | Method | Criterion |
|---|---|---|
| Purity | HPLC at 214 nm | ≥99.0% peak area |
| Identity (MW) | ESI-MS | ~4,813.5 ± 1.5 Da |
| Appearance | Visual | White to off-white powder |
| Peptide Content | AAA / elemental | ≥80% net peptide |
| Residual Moisture | Karl Fischer | ≤3% |
| Linker Integrity | HPLC-ELSD / LC-MS/MS | Intact C20 linker (bulk) |
Tiered Wholesale Pricing
| Kit size | Code | List price |
|---|---|---|
| 10 mg × 10 vials | TR10 | US$48 |
| 15 mg × 10 vials | TR15 | US$53 |
| 20 mg × 10 vials | TR20 | US$69 |
| 30 mg × 10 vials | TR30 | US$90 |
| 40 mg × 10 vials | TR40 | US$116 |
| 50 mg × 10 vials | TR50 | US$143 |
| 60 mg × 10 vials | TR60 | US$169 |
US$48–169 per kit (10 vials), from our published wholesale price list; tiered volume discounts apply (see the tier table) — source:wholesale price list (PDF, updated 2026-08-08).
| Volume | Discount | For |
|---|---|---|
| 1 kit | List price | Evaluation; competitive analysis |
| 5+ kits | 10% off | Initial portfolio expansion |
| 20+ kits | 20% off | Mid-size distributors |
| 50+ kits | 30% off | Regional distributors |
FAQ
How does Tirzepatide differ from Semaglutide mechanistically?
Semaglutide activates only GLP-1R. Tirzepatide activates both GIPR and GLP-1R — the GIP component adds insulinotropic effects, improved lipid handling, and better insulin sensitivity. Read the full comparison in our GLP-1 Buyer's Guide →
Why is Tirzepatide more expensive than Semaglutide?
Three factors: longer sequence (39 vs 31 AA → more coupling steps, higher material costs), more challenging purification, and higher demand relative to capacity (Tirzepatide is in 'differentiation' phase with growing demand).
What salt form is your Tirzepatide?
Standard is the acetate salt. If your protocol requires Na, TFA, or another counterion, specify in your inquiry — salt form can be adjusted during the final purification/lyophilization stage.
How do you confirm the identity — not just purity — of Tirzepatide?
Every batch undergoes both HPLC (purity, ≥99% peak area) AND ESI-MS (identity, confirming MW ~4,813.5 Da). For bulk orders: linker integrity by HPLC-ELSD or LC-MS/MS to confirm intact C20 fatty diacid conjugation.
All products are manufactured for laboratory research purposes only. Tirzepatide is labeled FOR LABORATORY RESEARCH USE ONLY. Not for human or veterinary use, diagnosis, treatment, prophylaxis or any clinical, cosmetic, dietary or household application. Not a dietary supplement, pharmaceutical ingredient, cosmetic ingredient or approved drug substance. Buyers are responsible for verifying the legal status of importation and possession in their destination country. GLP-1/GIP dual-agonist analogues are prescription medicines in many jurisdictions — buyers must confirm the legal status of importation and possession, and hold any required authorisation.
Ready to Source Tirzepatide?
Premium dual-agonist differentiation. Tiered pricing up to 30%. COA + MS + linker integrity with every bulk order.